PT-141 (Bremelanotide) Anesthesia and Perioperative Interaction

What Is Bremelanotide and How Does It Work?

Bremelanotide is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. It acts as a non-selective agonist at melanocortin receptors, primarily MC1R, MC3R, and MC4R. The FDA approved it in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. [1]

Receptor Pharmacology

Activation of MC4R in the central nervous system modulates sexual desire pathways. The same receptor subtype also influences autonomic tone, which is why cardiovascular effects appear alongside the drug's intended action. MC3R activation affects energy balance and may modulate peripheral vascular resistance. [2]

Pharmacokinetics Relevant to Surgery Timing

Bremelanotide is administered as a 1.75 mg subcutaneous injection approximately 45 minutes before anticipated sexual activity. Peak plasma concentration (Tmax) occurs at about 1 hour. The terminal elimination half-life is approximately 2.7 hours. By 12 hours post-dose, plasma levels fall below levels associated with measurable hemodynamic change in clinical pharmacology studies. [1]

This half-life is short on paper. The practical concern is not prolonged drug exposure; it is the magnitude and timing of the peak hemodynamic effect relative to induction of anesthesia.

Hemodynamic Effects: The Core Perioperative Risk

Blood pressure and heart rate changes are the most clinically significant concerns for anyone scheduled for surgery or a procedure requiring sedation. The Vyleesi prescribing information states that bremelanotide transiently decreases heart rate and increases blood pressure. [1]

Magnitude of Blood Pressure Change

In the phase III program that supported FDA approval (the RECONNECT trials, two randomized controlled studies, each with approximately 600 premenopausal women with HSDD), the mean maximum increase in systolic blood pressure was approximately 6 mmHg and diastolic blood pressure approximately 3 mmHg, occurring within the first 12 hours post-dose. [3]

These averages understate individual variability. Some patients experienced systolic increases exceeding 20 mmHg. Hypertension at baseline is therefore a contraindication in the labeling. The FDA label explicitly states: "Do not use Vyleesi in patients with cardiovascular disease or uncontrolled hypertension." [1]

Reflex Bradycardia and Heart Rate Effects

Bremelanotide also produces a mean decrease in heart rate of approximately 5 beats per minute, beginning within 12 hours of dosing. [1] This reflex bradycardia, in the context of a patient already receiving vagolytic or vagotonic anesthetic agents, creates unpredictable hemodynamic territory. Agents such as succinylcholine, neostigmine, or high-dose opioids each independently affect heart rate. Layering bremelanotide's autonomic effects onto these agents raises the risk of intraoperative dysrhythmia or hypotension.

Why Anesthesiologists Flag This Drug

Standard pre-anesthesia assessments classify any agent capable of producing a 20 mmHg systolic change as hemodynamically active. Bremelanotide meets this threshold in a meaningful subset of users. Most anesthesia departments follow the American Society of Anesthesiologists (ASA) framework of identifying and managing drugs that affect cardiovascular tone in the perioperative window. [4]

The 24-to-48-Hour Washout Recommendation

Most anesthesiologists advise stopping bremelanotide at least 24 hours before an elective procedure. Given the 2.7-hour half-life, five half-lives (approximately 13.5 hours) clears roughly 97% of the drug. The 24-hour recommendation builds in margin for outlier pharmacokinetics, including patients with mild renal or hepatic impairment who clear the drug more slowly. [1]

Renal Impairment Consideration

The FDA label notes that bremelanotide exposure increases in patients with renal impairment. In subjects with severe renal impairment (creatinine clearance <30 mL/min), AUC increased approximately 1.7-fold compared with subjects with normal renal function. [1] For these patients, a 48-hour washout before anesthesia is a more conservative and defensible choice.

Hepatic Impairment Consideration

Mild to moderate hepatic impairment does not substantially alter bremelanotide pharmacokinetics. Severe hepatic impairment data are limited, and the label recommends against use in this population. [1] If a patient with severe hepatic impairment presents for surgery and has used bremelanotide, extend the washout window to 48 hours and involve hepatology in perioperative planning.

Emergency Procedures

Elective washout is not always possible. When a patient requires emergency surgery within 24 hours of a bremelanotide dose, the anesthesia team should be informed immediately. Management includes:

• Continuous intraoperative arterial line blood pressure monitoring
• Avoiding anesthetic combinations known to compound bradycardia (e.g., high-dose remifentanil with beta-blockade)
• Having phenylephrine or norepinephrine immediately available for vasopressor support
• Reviewing the ECG for baseline conduction abnormalities before induction [4]

Interaction With Specific Anesthetic Drug Classes

Volatile Anesthetic Agents

Agents such as sevoflurane and desflurane produce dose-dependent reductions in systemic vascular resistance and cardiac output. Bremelanotide's own vasopressor effect could partially mask these reductions, making titration of inhalational depth less predictable. Conversely, as bremelanotide clears during a long procedure, the unopposed vasodilatory effect of the volatile agent may produce unexpected hypotension. [4]

Propofol and Total Intravenous Anesthesia (TIVA)

Propofol is a vasodilator and negative inotrope. Patients who received bremelanotide within 24 hours and then receive propofol for induction may experience a sharper initial blood pressure drop than expected. Dose reduction of the induction bolus and slower injection rates are reasonable precautions. [4]

Opioids

High-dose opioids, particularly remifentanil, produce vagally mediated bradycardia. Combined with bremelanotide's own heart rate reduction of approximately 5 bpm, the additive effect on heart rate is clinically relevant. The package insert for bremelanotide notes interactions with opioids specifically in the context of nausea potentiation as well. Naloxone should be immediately available. [1]

Spinal and Epidural Anesthesia

Neuraxial techniques reduce sympathetic tone and can cause significant hypotension, particularly in hypovolemic patients. A patient who received bremelanotide within 12 hours and then undergoes spinal anesthesia may experience greater-than-anticipated blood pressure drops. Pre-loading with crystalloid and having a vasopressor drawn up before needle placement is standard practice in these cases. [4]

Nausea: The Second Major Perioperative Concern

Nausea is the most common adverse effect of bremelanotide. In the RECONNECT trials, nausea occurred in approximately 40% of patients who received bremelanotide 1.75 mg. [3] About 13% of subjects reported severe nausea. [1]

Interaction With Anesthetic-Induced Nausea

Postoperative nausea and vomiting (PONV) is already a common anesthesia complication. Female sex, non-smoking status, history of PONV, and opioid use each independently raise PONV risk. [5] Bremelanotide use within 24 hours of a procedure adds nausea risk to an already susceptible population.

The Apfel score is the standard four-factor risk model used to predict PONV. [5] Any patient with a bremelanotide dose on board effectively carries an additional nausea burden that the Apfel score does not capture. Anesthesiologists should consider combination antiemetic prophylaxis (e.g., ondansetron plus dexamethasone) in these patients even for procedures that would otherwise warrant only single-agent prophylaxis.

Aspiration Risk

Persistent nausea delays gastric emptying. The ASA fasting guidelines require a minimum 6-hour fast for solid food before elective procedures. [6] If a patient reports vomiting from a recent bremelanotide dose, the elective procedure should be postponed until the patient's gastric contents are reliably cleared and vomiting has resolved completely.

Can I Drink Alcohol on PT-141 (Bremelanotide)?

Alcohol and bremelanotide should not be combined on the same day. Both agents lower blood pressure through separate mechanisms, alcohol by peripheral vasodilation and suppression of vasopressin, and bremelanotide by its autonomic effects. Same-day co-use compounds orthostatic hypotension risk. [1]

Nausea Compounding

Alcohol independently irritates gastric mucosa and activates the chemoreceptor trigger zone. With bremelanotide already producing nausea in approximately 40% of users, adding alcohol substantially increases the likelihood of vomiting. Severe vomiting after bremelanotide led to treatment discontinuation in a subset of clinical trial participants. [3]

Practical Guidance for Patients

• Avoid alcohol for at least 12 hours before a bremelanotide dose.
• Do not drink alcohol on the same day as a bremelanotide injection.
• If alcohol was consumed within the prior 6 hours, skip the bremelanotide dose for that day.

The FDA label does not state a specific alcohol warning with numerical thresholds, but the hemodynamic and GI rationale for avoiding co-use is well-supported by the drug's pharmacology. [1]

Other Drug Interactions Worth Noting in Perioperative Context

Naltrexone

Bremelanotide is a melanocortin agonist, not an opioid, but the FDA label lists a pharmacodynamic interaction with naltrexone. Co-administration may alter the expected hemodynamic response. Patients on naltrexone for alcohol use disorder or opioid dependence should have this noted in the pre-anesthesia medication reconciliation. [1]

Antihypertensives

Patients on calcium channel blockers, ACE inhibitors, or beta-blockers who use bremelanotide may show attenuated blood pressure rises compared with the mean observed in trials. However, the bradycardic effect may be potentiated in patients on beta-blockers, increasing the risk of significant intraoperative bradycardia. [1]

Anticholinergic Drugs

Atropine or glycopyrrolate are sometimes used intraoperatively to treat bradycardia. If bremelanotide-related bradycardia is suspected intraoperatively, these agents remain effective and are appropriate rescue therapy. [4]

Perioperative Management Framework

The following protocol reflects a synthesis of the bremelanotide FDA label, ASA perioperative medication management principles, and the hemodynamic data from the RECONNECT trials. It is intended for clinical use pending physician review and individualization.

Pre-procedure (elective surgery):

1. Ask all patients of reproductive age whether they use bremelanotide as part of routine pre-anesthesia medication reconciliation.
2. Instruct patients to hold the last bremelanotide dose at least 24 hours before the procedure; extend to 48 hours if creatinine clearance is <30 mL/min.
3. Obtain a baseline ECG if the patient reports recent bremelanotide use within the past 48 hours.
4. Document last dose time in the pre-anesthesia record.

Intraoperative:

5. If a patient received bremelanotide within 24 hours, place an arterial line for continuous blood pressure monitoring in procedures lasting more than 30 minutes.
6. Reduce propofol induction dose by 10 to 20% and inject slowly (over 60 seconds or more) to mitigate additive hypotension at induction.
7. Minimize high-dose opioid boluses at induction if heart rate is already <60 bpm.
8. Draw up a vasopressor (phenylephrine 100 mcg/mL or norepinephrine 8 mcg/mL) before induction.

Postoperative:

9. Use combination antiemetic prophylaxis (ondansetron 4 mg IV plus dexamethasone 4 mg IV) in all patients with recent bremelanotide use, regardless of baseline Apfel score.
10. Monitor blood pressure and heart rate every 5 minutes for the first 30 minutes in the post-anesthesia care unit (PACU).

What Patients Should Tell Their Surgical Team

Patients sometimes omit sexual health medications from medication lists because of embarrassment. This omission can be clinically consequential with bremelanotide. The blood pressure and heart rate effects are pharmacologically real and carry anesthesia implications. [1]

Before Scheduling Surgery

At the time of surgical booking, inform the nurse or coordinator that you use bremelanotide. The pre-anesthesia questionnaire should include it under current medications. Do not list it under vitamins or supplements since it is a prescription peptide with documented cardiovascular effects.

The Day Before Surgery

Confirm with your anesthesia provider that they have noted your last bremelanotide dose time. Bring the Vyleesi auto-injector to show the lot number and packaging if the provider has questions about the specific formulation. [1]

After Surgery

Wait at least 24 hours after your procedure and until you are no longer taking opioid pain medication before resuming bremelanotide. Opioid-induced nausea combined with bremelanotide-induced nausea creates a high vomiting burden in the early postoperative period.

Special Populations

Patients With Pre-Existing Hypertension

The FDA label contraindicates bremelanotide in patients with uncontrolled hypertension or cardiovascular disease. [1] If a patient with managed hypertension presents for surgery after recent bremelanotide use, tighter intraoperative blood pressure targets and more frequent monitoring are appropriate. A systolic blood pressure target of 90 to 140 mmHg intraoperatively (rather than the usual broader tolerance) is a reasonable perioperative goal.

Patients Using Combined Hormonal Contraception

Bremelanotide reduces the Cmax and AUC of orally administered drugs by delaying gastric emptying. [1] Patients taking oral contraceptive pills on the same day as bremelanotide should take the pill at least 1 hour before the bremelanotide injection to avoid reduced contraceptive absorption. This is not a perioperative safety issue per se, but it is relevant context for reproductive-age patients undergoing elective procedures who may resume bremelanotide postoperatively. [1]

According to the Vyleesi prescribing information: "Bremelanotide may reduce the rate and extent of absorption of orally administered drugs due to its effect on gastrointestinal motility." [1] This applies to oral pre-anesthetic medications as well. Any oral pre-medication given within 2 hours of a bremelanotide dose may be absorbed more slowly than expected.